Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qi-Gui-Yin formula (also known as Qiguiyin) is a traditional Chinese medicine (TCM) herbal formula developed by the Beijing Institute of Traditional Chinese Medicine. It is composed of five herbal ingredients: Astragalus mongholicus (Astragali Radix), Angelica sinensis (Angelicae sinensis Radix), Lonicera japonica (Lonicerae Japonicae Flos), Artemisia annua, and Reynoutria japonica (Polygoni Cuspidati Rhizoma et Radix). Qi-Gui-Yin is primarily developed for the treatment of severe pneumonia, particularly infections caused by multi-drug resistant (MDR) *Pseudomonas aeruginosa*. It works by suppressing bacterial quorum sensing, inhibiting biofilm formation, and downregulating active efflux pumps, thereby restoring sensitivity to antibiotics like imipenem and levofloxacin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qi-Gui-Yin formula.